Blue Jet Healthcare Limited share price
NSE: BLUEJET · ISIN INE0KBH01020
Key numbers
- Market cap
- ₹ 9,899 Cr
- Current price
- ₹ 570.65
- 52-week high / low
- ₹ 693 / 325
- Stock P/E
- 42.2
- Book value
- ₹ 78.4
- Dividend yield
- 0.21%
- ROCE
- 26.5%
- ROE
- 19.9%
- Debt to equity
- 0.03
- Sales growth (3 yrs)
- 9.4%
- Profit growth (3 yrs)
- 15.7%
- 1-year return
- -15.1%
About Blue Jet Healthcare Limited
Blue Jet Healthcare Limited engages in the manufacturing and sale of artificial sweeteners, pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in products. It provides contrast media intermediates, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related supplies to healthcare, pharma, animal feed, and food and beverages industries. It has operations in India, Norway, France, the United States, Denmark, Thailand, Spain, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 340 | 355 | 192 | 235 | 293 |
| Operating profit | 140 | 121 | 47 | 71 | 98 |
| Net profit | 110 | 91 | 40 | 64 | 78 |
| EPS (₹) | 6.35 | 5.26 | 2.32 | 3.71 | 4.51 |
Concall summary (2026-08-07)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- At Unit 3, backward integration project continues to progress well and remains on -track with commercial contribution expected during the second half of FY27.
- During FY27, we expect to launch 3 candidates within the Contrast Media segment alongside initiating pilot activities for a new high-intensity sweetener.
Growth & demand
- FY26 was a year of building the foundation for the next phase of growth, and we are pleased to see the early benefits of these investments beginning to reflect in our operating performance.
- The successful completion of our QIP , marks an important milestone in Blue Jet's growth journey.
Margins & costs
- During the quarter, we reported revenue from operations of INR293 crores and an EBITDA of INR98 crores, reflecting healthy sequential improvement.
- Our reported gross margin at 53% is a reduction of 3% over previous quarter and reported operating EBITDA is 33.5% compared to 30.4% in the previous quarter, an increase of 3%.
Capex & expansion
- Our vision for Vizag , extends well beyond capacity expansion.
- A significant part of Phase 1 capacity has been planned against identified customer opportunities and business visibility which we believe will help shorten the journey from commissioning to commercialization.
Balance sheet & cash
- This expansion of gross EBITDA margin is on account of operating leverage on a higher sale.
Peers in Biotechnology
Data for information only, not investment advice. Prices end of day.